Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?
- 7 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 40 (7), 3015-3019
- https://doi.org/10.1007/s10067-021-05724-5
Abstract
The coronavirus disease 2019 (COVID-19) is the largest public health emergency in recent times. A significant number of patients develop a severe form of COVID-19 characterized by coagulopathy, organ failure, and elevated mortality. In addition, an unusually high frequency of antiphospholipid antibodies (aPLs) has been found in patients with COVID-19. These clinical and serological manifestations closely resemble those seen in the antiphospholipid syndrome (APS), especially in its catastrophic form, suggesting a role of aPLs in immune-associated coagulopathy. However, government bodies such as the American Society of Hematology have spoken out against the systematic search for aPLs in patients with COVID-19. In an attempt to bridge the gap on this hot topic, we conducted a comprehensive review of currently available cohort studies and case series systematically evaluating aPLs in COVID-19 patients. In this Perspective, we seek to identify both the frequency and the type of aPLs found in patients with COVID-19, as well as the potential association of these aPLs with vascular thrombosis and other distinctive characteristics of COVID-19. Furthermore, we investigated whether there is evidence that allows us to define the occurrence of aPLs in COVID-19 as an epiphenomenon, as has been observed in other systemic viral infections, or as antibodies against self-antigens bearing hallmarks that suggest a pathogenic role in immune-mediated thrombosis. Defining whether aPLs represent an epiphenomenon or they are actually involved in hemostatic abnormalities of COVID-19 is crucial both for uncovering novel mechanisms of immune-mediated thrombosis and for identifying potential prognostic biomarkers in this devastating disease.This publication has 32 references indexed in Scilit:
- Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19The New England Journal of Medicine, 2020
- Lupus anticoagulant is frequent in patients with Covid‐19Journal of Thrombosis and Haemostasis, 2020
- High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort studyIntensive Care Medicine, 2020
- Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19The New England Journal of Medicine, 2020
- Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five casesTranslational Research, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Lupus anticoagulant identifies two distinct groups of patients with different antibody patternsThrombosis Research, 2018
- Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β2‐Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid SyndromeArthritis & Rheumatology, 2015
- Obstetric and vascular APS: Same autoantibodies but different diseases?Lupus, 2012
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006